SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

NCT02509195 | Completed Phase 4

• 2 other identifiers: SSAT0642014-004970-40
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to identify the effects that ageing may have on the drug levels, the safety and the efficacy of Dolutegravir. These effects will be measured in people who are aged 60 or over and taking antiretroviral therapy for HIV infection. Dolutegravir is a newly licenced anti HIV medication, which belongs to a class of drugs called Integrase Inhibitors. It is taken with two other wellknown agents, Abacavir and Lamivudine, as part of a one tablet once a day regimen, called Triumeq. There is little data available on Dolutegravir in the context of older age. The HIV population is ageing and the investigators know that older age can significantly change the effects and side effects of medications, including that of antiretrovirals. The investigators aim to investigate the treatment outcomes in older people taking Dolutegravir including the tolerability, efficacy and safety of the drug. The study will also assess the quality of life (wellbeing of individuals) and cognition (mental abilities) of people aged 60 or over, taking Dolutegravir. The results from this study may inform treatment choices and monitoring in this population in the future. The duration of involvement in the study will be 6 months with an additional screening visit and a checkup visit 10 days after end of study visit.

Conditions

HIV

Outcome Measures

Primary Outcomes (1)

• Steady state plasma concentrations of dolutegravir when administered to HIV-infected individuals over the age of 60/65 years.

  Day 28

Secondary Outcomes (10)

• Safety on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater - measured by Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events.

  Up to day 190

• Tolerability on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater- measured by Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events.

  Up to day 190

• Maintenance of HIV viral load control on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater.

  Up to day 190

• Quality of life on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater.- Measured by questionnaire

  Up to day 190

• Sleep Quality on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater - Measured by questionnaire

  Up to day 190

Study Arms (1)

Switch to Triumeq

EXPERIMENTAL

HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).

Drug: Triumeq

Interventions

Triumeq DRUG

Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.

Also known as: abacavir/lamivudine/dolutegravir

Switch to Triumeq

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-1 infected males or females
• Has voluntarily signed informed consent after having enough time to consider the study information.
• Is willing to comply with the protocol requirements
• Documentation that the subject is negative for the HLA-B\*5701 allele, either on historical sample or if none available, at screening.
• Aged 60 years and over (approximately 70% of the study participants will be ≥65 year of age), willing to switch therapy as per study protocol with no previous use of dolutegravir
• Plasma HIV RNA \< 50 copies/mL at screening (single re-test allowed) and on at least one other occasion over the last 6-8 months
• Has a CD4 cell count at screening \>50 cells/mm3
• Currently receiving a stable antiretroviral regimen with no antiretroviral drug switches for at least 3 months prior to planned study baseline.
• No previous clinically-significant resistance documented on HIV-1 genotypic resistance to NRTIs and INIs
• Subjects in good health upon medical history, physical exam, and laboratory testing and with a clinically managed cardiovascular disease in the opinion of the Investigator
• Body mass over 40 kg and body mass index (BMI) above or equal to 18 and below 35
• Male subjects who are heterosexually active must be willing to use appropriate and consistent dual method contraception during heterosexual intercourse with women of child bearing potential, from screening through to one month post completion of the study. The following combined contraceptive methods are acceptable (please see appendix 3):
• Double barrier method:
• Male Condom combined with a Female Diaphragm with or without a vaginal spermicide\* (foam, gel, film, cream, or suppository)
• Male Condom combined with a Cervical cap\*\* (with spermicide)

You may not qualify if:

• History or presence of allergy to the study drugs or their components
• Infected with HIV-2
• Using any concomitant therapy disallowed as per SPC for the study drugs. The SPC of a drug is updated regularly. The most recent version can be found on http://www.medicines.org.uk/emc/
• Known acute viral hepatitis including, but not limited to, A, B, or C
• Known chronic hepatitis B and/or C
• Tests newly positive for active Hepatitis B (HBsAg positive), or active Hepatitis C (PCR positive) at screening visit
• Any investigational drug within 30 days prior to the trial drug administration
• Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥1.5xULN (with \>35% direct bilirubin)
• Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification
• Moderate or severe renal impairment (creatinine clearance \< 50ml/min)
• Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
• Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with the assessments or completion of the trial.

Sponsors & Collaborators

• St Stephens Aids Trust: lead
• ViiV Healthcare: collaborator

Study Sites (1)

St Stephen's Centre, Chelsea & Westminster Hospital

London, SW10 9NH, United Kingdom

Location

MeSH Terms

Interventions

abacavir, dolutegravir, and lamivudine drug combination

Study Officials

• Marta Boffito

  St Stephen's AIDS Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2015
• First Posted: July 27, 2015
• Study Start: August 4, 2015
• Primary Completion: February 13, 2017
• Study Completion: July 24, 2017
• Last Updated: February 28, 2018

Record last verified: 2018-02

Locations

GB (1)